# mTNBC (NCT04468061)

> Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04468061
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer; Triple Negative Breast Cancer; PD-L1 Negative
- Interventions: Sacituzumab Govitecan; Pembrolizumab
- Enrollment: 110
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on mTNBC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mtnbc-nct04468061